New study tracks how well nintedanib works over time for scleroderma lung disease
NCT ID NCT07080125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meaning it just watches what happens in real-world care, without giving anyone a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nintedanib (Ofev®)
- What this could lead to
- If successful, this study could confirm that nintedanib helps slow lung decline and improve survival in people with systemic sclerosis-associated lung disease.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. It also only includes patients already enrolled in a registry, which may limit how well findings apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
EUSTAR Registry
Basel, 4051, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a JAK inhibitor halt rapid lung decline?
- Could a vibrating platform help people with stiff lungs breathe easier?
- Massive study tracks lung disease progression in 4,000 patients
- New MRI method could spot lung damage without radiation
- New pill aims to halt lung scarring in thousands
- New combo therapy aims to halt lung scarring in scleroderma